Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

is open and Janssen plans to enroll 110 patients worldwide.
  • Phase Ib/II dose escalating study of ibrutinib in combination with R-CHOP in patients with newly diagnosed CD20 positive non-Hodgkin's lymphoma. The purpose of this study is to identify a safe and tolerable dose of ibrutinib in combination with R-CHOP, once a safe dose is established the study will expand and report responses of this combination in patients with newly diagnosed DLBCL. This global, multi-center study, conducted by Janssen, is open and Janssen plans to enroll 33 patients.
  • Phase II study of ibrutinib in subjects with relapsed or refractory multiple myeloma (MM): This is a Phase II, multi-center, open-label trial designed trial to assess the safety and efficacy of ibrutinib single agent and in combination with dexamethasone in subjects with relapsed or relapsed MM. This study is conducted by Pharmacyclics and is currently exploring ibrutinib administration at 560 mg in combination with dexamethasone. Two further cohorts are planned to be explored; 840 mg with dexamethasone and 840 mg as a single agent. The Company anticipates an update on this study will be provided by year end 2013.
  • Phase II open-label, multicenter, single-arm study of monotherapy ibrutinib in subjects with relapsed or refractory follicular lymphoma. The primary endpoint of this study is objective response rate. Janssen plans to enroll 110 patients in this study.
  • PCYC has received Orphan Drug and Fast Track designation for ibrutinib treatment of chronic lymphocytic leukemia last year. The FDA has also granted Orphan Drug and Fast Track designation most recently to ibrutinib for the treatment of mantle cell lymphoma.  A US orphan drug designation provides the drug developer with several benefits and incentives related to the orphan drug, including a 7-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified indication. Fast tra
    '/>"/>

    SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... Ras Al Khaimah, UAE (PRWEB) October 30, 2014 ... the appointment of Dr. James A. Manganello, Chairman of the ... (NSCEC) of The Bahamas. The appointment was made by ... The Bahamas on September 24th, 2014. , More ... Cell Therapy and Research Bill , Prime Minister Perry Christie ...
    (Date:10/30/2014)... BASKING RIDGE, N.J. , Oct. 30, 2014 /PRNewswire/ ... announced that it will hold a conference call and ... 8:30 a.m. EST to discuss its third quarter 2014 ... access the conference call by dialing (888) 347-1165 for ... conference call will be webcast live under the investor ...
    (Date:10/27/2014)... 2014 Ryan Carfley , Managing Partner ... sit down with Bryan Hamilton, the publisher of the Triangle ... talent in the Research Triangle region of North Carolina. , ... at the roundtable include the role of social media ... work/life balance and the unique role that Millennials play in ...
    (Date:10/27/2014)... and TORONTO , ... ( www.generex.com ) (OTCQB: GNBT) today announced two ... response triggered by its novel proprietary cancer immunotherapeutic ... in breast cancer patients. The AE37 cancer vaccine ... Antigen Express, Inc. ( www.antigenexpress.com ). The presentations ...
    Breaking Biology Technology:Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
    ... , , TUSTIN, Calif., Aug. 27 ... it will release its financial results for the first quarter of fiscal ... host a conference call and webcast to discuss the results at 11:30 ... senior management will discuss financial results for the first quarter ended July ...
    ... , , , SEATTLE, ... that the Company will hold an Analyst Day on Thursday, September 24, ... A live audio webcast of the presentation will be accessible through the ... are unable to listen to the live webcast, it will be archived ...
    ... , , , ... Aug. 27 Airo, recognized maker of the world,s best ... is available for delivery Q4 of 2009. Airo is releasing ... explosive environments like Petroleum, Chemicals, Fertilizer, Coal, Propane, Fuel Distribution, ...
    Cached Biology Technology:Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results 2Airo Wireless Announces the Release of the Intrinsically Safe A25is Cell Phone/PDA 2
    (Date:10/28/2014)... from North America, Europe and China have published a ... of Sciences that reveals important details about key ... planet., From strange and exotic algae, mosses, ferns, trees ... grains and vegetables we eat and the ornamental plants ... over a billion years of history., "Our study generated ...
    (Date:10/28/2014)... be building a hybrid micro-grid which will integrate ... in the region, the hybrid micro-grid will test ... diesel, storage and power-to-gas technologies, and ensure these ... built under the new Renewable Energy Integration Demonstrator- ... located offshore at Semakau Landfill and is expected ...
    (Date:10/27/2014)... in German . ... interior via electrical signals, they communicate with each other ... messenger substances, the neurotransmitters, are stored in vesicles at ... these vesicles fuse with the cell membrane and release ... lost, synapses always have some readily releasable vesicles on ...
    Breaking Biology News(10 mins):New study uses DNA sequences to look back in time at key events in plant evolution 2New study uses DNA sequences to look back in time at key events in plant evolution 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3Synapses always on the starting blocks 2Synapses always on the starting blocks 3
    ... Inc. (NYSE:,SXE), a leading provider of systems integration ... today that it has entered into a,definitive agreement ... operations and information technology services,company. The purchase price ... certain working capital and other adjustments as of ...
    ... of Food Research have detected subtle changes that may make ... With support from the Food Standards Agency and the ... diet could control these changes and delay or reverse the ... genes that play a role in the very earliest stages ...
    ... in dolphins from Port Phillip Bay and the Gippsland ... contributing factor to dolphin deaths. Researchers from ... mercury found in the dolphins were within a range ... were higher than mercury levels found in populations around ...
    Cached Biology News:Stanley to Acquire Oberon Associates 2Stanley to Acquire Oberon Associates 3Stanley to Acquire Oberon Associates 4'Addicted' cells provide early cancer diagnosis 2Mercury contamination found in stranded Victorian dolphins 2
    ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
    Anti-Human IFN-Gamma Receptor Chain 2 (beta chain) [CD119], Rabbit serum, NON-neutralizing polyclonal antibody...
    Anti-BAR Immunogen: Peptide of aa 3-21 from human Bar Available Date: 38226...
    ... UbcH7 interacts with the ... c-Cbl RING domain. Evidence suggests ... in both the degradation of ... of certain N-a -acetylated proteins ...
    Biology Products: